BioTuesdays

Category - Markets

Merus Logo
Markets

HCW starts Merus NV at buy; PT $23

H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...

June 26, 2020
Mersana Therapeutics Logo
Markets

BTIG ups Mersana Therapeutics PT to $32 from $21

BTIG raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $32 from $21, saying the company’s STING agonist antibody-drug conjugates look compelling on the evolving immunoncology landscape. The stock closed...

June 24, 2020
Brookline Logo
Markets

Brookline boosts life sciences equity research

Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team.  With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...

June 24, 2020
Markets

HCW starts Aprea Therapeutics at neutral; PT $30

H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...

June 22, 2020
Tocagen Logo
Markets

Ladenburg starts Forte Biosciences at buy; PT $60

Ladenburg Thalmann launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $60 price target. The stock closed at $14.31 on June 19. Forte is focused on the treatment of inflammatory skin diseases...

June 22, 2020
Annovis Logo
Markets

Maxim starts Annovis Bio at buy; PT $12

Maxim Group launched coverage of Annovis Bio (NYSE American:ANVS) with a “buy” rating and $12 price target. The stock closed at $5 on June 17. Annovis’ ANVS401 is a disease-modifying agent for chronic neurodegenerative...

June 18, 2020
Synthetic Biologics Logo
Markets

Maxim starts Synthetic Biologics at buy; PT $1.50

Maxim Group initiated coverage of Synthetic Biologics (NYSE American:SYN) with a “buy” rating and price target of $1.50. The stock closed at 47 cents on June 17. The company is focused on the gut microbiome with two...

June 18, 2020
Itamar Medical
Markets

SVB Leerink starts Itamar Medical at OP; PT $30

SVB Leerink launched coverage of Itamar Medical (NASDAQ, TASE:ITMP) with an “outperform” rating and $30 price target. The stock closed at $16.01 on June 11. “We see Itamar as an underappreciated high growth/gross margin...

June 12, 2020
Selecta Biosciences
Markets

Stifel cuts Selecta Biosciences to hold with $4 PT

Stifel downgraded Selecta Biosciences (NASDAQ:SELB) to “hold” from “buy” with a price target of $4 after the company inked a licensing deal for its SEL-212 drug candidate for the treatment of severe chronic gout with...

June 12, 2020